Medicines labeled for the same conditions
Alternatives to adalimumab-aacf
9 other medicines are given the same way (subcutaneous) and in the same FDA class as adalimumab-aacf or labeled mainly for the same use (rheumatoid arthritis); the others include 4 tumor necrosis factor blockers, 2 interleukin-6 receptor antagonists and 1 folate analog metabolic inhibitor (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as adalimumab-aacf?
Rheumatoid arthritis lists all 46 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Adalimumab-aacf | this medicine | none listed | n/a | Yes | No current entry |
| Adalimumabtumor necrosis factor blocker | Rheumatoid arthritis, Crohn's disease and ulcerative colitis, Psoriasis | none listed | $1,587.82 per mL 40 mg/0.4 mL | Yes | No current entry |
| Methotrexatefolate analog metabolic inhibitor | Rheumatoid arthritis, Psoriasis | none listed | $289.37 per mL 25 mg/0.5 mL autoinj | Yes | In shortage |
| Tocilizumabinterleukin-6 receptor antagonist | Rheumatoid arthritis | none listed | $821.00 per mL 162 mg/0.9 mL autoinjct | Yes | No current entry |
| Adalimumab-ryvk | Rheumatoid arthritis, Crohn's disease and ulcerative colitis, Psoriasis | none listed | $499.12 per unit 40 mg/0.4 mL autoinjector | Yes | A presentation being discontinued |
| Etanercepttumor necrosis factor blocker | Rheumatoid arthritis, Psoriasis | none listed | $2,084.14 per mL 25 mg/0.5 mL syringe | Yes | No current entry |
| Sarilumabinterleukin-6 receptor antagonist | Rheumatoid arthritis | none listed | $2,075.30 per mL 200 mg/1.14 mL pen injection | Yes | No current entry |
| Abataceptselective t cell costimulation modulator | Rheumatoid arthritis | none listed | $1,469.23 per mL 125 mg/mL syringe | No | No current entry |
| Certolizumabtumor necrosis factor blocker | Rheumatoid arthritis, Crohn's disease and ulcerative colitis, Psoriasis | none listed | $6,094.02 per syringe 2x200 mg/mL syringe kit | Yes | No current entry |
| Golimumabtumor necrosis factor blocker | Rheumatoid arthritis, Crohn's disease and ulcerative colitis | none listed | $12,890.32 per mL 50 mg/0.5 mL pen injec | Yes | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Adalimumab-aacf: the full record
- label, generics, price, shortages, recalls